SANOFI: Sanofi and Regeneron offer Praluent® (alirocumab) at a new reduced U.S. list price
SAREPTA THERAPEUTICS, INC.: Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53
Alerts Sign-up
